More recent and comprehensive metabolic studies, undertaken in our laboratory and by the Myers’ laboratory, have revealed TP53 status as a determinant of the metabolic phenotype and therapeutic response in HPV-negative SCCHN [13,15]. The gene discussed is TP53; the disease is head and neck squamous cell carcinoma.